The activities of mecillinam and ampicillin, alone and in combination, were evaluated in mice infected with the LT-2 strain of Salmonella typhimurium. The minimal inhibitory concentrations of mecillinam and ampicillin for this strain were, respectively, 6.2 and 0.4 ,tg/ml of culture medium. In vitro synergy was demonstrated. CF-1 mice inoculated intraperitoneally with 104 colony-forming units of the LT-2 strain were used in the therapeutic assessments. Treatment of subgroups with graded doses of the respective penicillins or their combination was initiated 24 h after inoculation and repeated at 6-h intervals for 5 consecutive days. Animals were observed during 21 days for mortality or sacrificed for quantitative cultures of spleen homogenates at the end of the treatment. Ampicillin in doses of -0.03 mg and mecillinam in doses of -0.5 mg reduced mortality rates from 77% in the saline-treated controls to a range of 0 to 47% (P< 0.05). The same doses of antibiotics also extended the median times to death and lowered significantly the means of splenic bacterial counts. When both drugs were combined in doses that were partially effective or subinhibitory alone, no synergistic effects were observed. These results showed that mecillinam and ampicillin given alone were effective in treating S. typhimurium infection but that combinations of the two drugs were not synergistic in controlling the course of infections.
The new 6,f-amidinopenicillanic acid derivative mecillinam has antibacterial activity against most Enterobacteriaceae, including the Salmonellae (10, 16) . Although mecillinam, like other beta-lactam antibiotics, acts to inhibit cell wall synthesis, it differs from other beta-lactam antibiotics by binding selectively to penicillin-binding protein 2 and by causing bacteria to assume enlarged spherical shapes that are osmotically stable (14, 15) . Lysis of bacteria then occurs, and studies with adenyl cyclase-deficient mutants of Escherichia coli suggest that cyclic adenosine monophosphate plays a role in mecillinam-induced lysis (1). Tybring and Melchior (17) and Neu (11) showed that the combination of mecillinam and ampicillin produced synergistic inhibition in vitro of some strains of Salmonellae. Mecillinam has been used to treat patients with typhoid fever in two studies, one of which reported satisfactory results (4) and the other of which reported treatment failures (8) . Because the murine infection with Salmonella typhimurium is similar to human typhoid fever with respect to the production of bacteremia and a sometimes fatal accumulation of organisms in the reticuloendothelial cells, we examined the activity of mecillinam in experimental S. typhimurium infections by comparing this activity with that of ampicillin. We have also examined combinations of the two drugs for possible synergistic effects in vivo.
MATERIALS AND METHODS
In vitro testing of antibiotic susceptibility. S. typhimurium LT-2 was used throughout this study. This strain is virulent in mice (3), resembling in this respect other Salmonella strains that have been employed in experimental mouse typhoid (7 In vivo effects of mecillinam and ampicillin given alone. The efficacies of mecillinam and ampicillin were studied in three consecutive experiments. The mortality among salinetreated control mice was 77% during the 21-day period of observation. As shown in Table 1 Our inability to show mecillinam-ampicillin synergy in experimental S. typhimurium infections actually may be in accord with the finding of Lorian and Atkinson (6) that S. typhimurium exposed to subinhibitory concentrations of ampicilhin or mecillinam was not more susceptible to the bactericidal action of serum and blood than were untreated bacteria. The disparity between our in vitro and in vivo results on synergy may reflect difficulties in standardizing definitions of synergy and deriving therapeutic applications from in vitro studies (29).
